Role of intracoronary ultrasound after high-pressure stent implantation

Increased CK-MB release is a “trade-off” for optimal stent implantation

OBJECTIVES

We sought to determine the impact of aggressive stent expansion on creatine kinase-MB isoenzyme (CK-MB) release and clinical restenosis.

BACKGROUND

Elevation of CK-MB after percutaneous coronary interventions has been associated with late mortality.

METHODS

We identified 989 consecutive patients who underwent intravascular ultrasound-guided stenting of 1,015 coronary lesions. Patients were divided into three groups according to stent expansion, defined as the ratio of final lumen over the reference lumen cross-sectional areas: Group 1 (ratio <70%, n = 117 patients with 126 lesions); Group 2 (ratio 70% to 100%, n = 551 patients with 562 lesions); Group 3 (ratio >100%, n = 321 patients with 327 lesions).

RESULTS

The peak CK-MB values increased significantly with increasing stent expansion: CK-MB = 3 to 5x normal occurred 16%, 18%, and 25% in Groups 1, 2, and 3, respectively, p = 0.02; CK-MB >5 times normal occurred 9%, 13%, and 16% respectively, p = 0.02. Conversely, at one year follow-up there was a stepwise decrease in target lesion revascularization (11% vs. 19% and 17%, respectively, p = 0.04) and major adverse cardiac events with increasing stent expansion. In addition, there was a trend toward lower mortality in Group 3 (9% vs. 4.4% vs. 4.0%, p = 0.07).

CONCLUSIONS

Intravascular ultrasound-guided stent overexpansion (final lumen greater than reference lumen cross-sectional area) is accompanied by a higher periprocedural CK-MB release but a lower target lesion revascularization and a trend toward lower mortality at one year. Increased periprocedural CK-MB release appears as a trade-off for optimal stent implantation and lower clinical restenosis.

Efficacy of postdeployment balloon dilatation for current generation stents as assessed by intravascular ultrasound

Adjunctive balloon dilatation strategy has been shown to improve optimal stent deployment. As improvements in current stent designs evolve, less adjunctive balloon dilatation may be needed. However, few data currently exist to support this practice. We evaluated 88 native coronary lesions treated with single stent implantation (Nir, Tristar or S670). Serial intravascular ultrasound was performed after successful stent deployment and again after adjunctive balloon dilatation. To investigate further the precise expansion characteristics of the stents, serial volumetric intravascular ultrasound analyses were performed in 40 patients with automated pullback. After adjunctive balloon dilatation, minimal stent area increased significantly, from 6.4 +/- 2.1 to 7.4 +/- 2.2 mm(2) (p <0.001). Volumetric analysis showed a corresponding increase in stent volume index (6.6 +/- 1.8 to 7.5 +/- 2.0 mm(3)/mm, p <0.001). In the analysis of cross sections at 0.5-mm axial intervals, the percentage of cross sections, where stent area was > or =80% of the average reference lumen area, increased from 51% to 78% (p <0.001). Similarly, the percentage of cross sections, where stent area was > or =90% of the average reference lumen area, increased from 29% to 56% (p <0.001) with postdilatation. Postdeployment high- pressure balloon dilatation improved minimal stent area and volumetric expansion throughout the stented segment.

Resource utilization and clinical outcomes of coronary stenting: a comparison of intravascular ultrasound and angiographical guided stent implantation

BACKGROUND

Intravascular ultrasound (IVUS) guided stent implantation studies have demonstrated that inadequate stent implantation can occur despite achieving an optimal angiographic result. Furthermore, IVUS-guided stent implantation has been shown to improve lesional acute gain. However, it is unknown whether the use of IVUS guidance during stent implantation is associated with improved acute and long-term clinical outcomes. Moreover, the additional procedural cost and time incurred with the use of IVUS-directed stent implantation has not been evaluated. Thus the purpose of this study was to determine whether IVUS-guided stent implantation is associated with improved clinical outcomes compared with angiographically guided stent implantation and to evaluate the difference in resource utilization between these respective stent deployment strategies.

METHODS

Data were collected on 278 consecutive patients in whom 455 stents were deployed in native coronary arteries. High-pressure (> or = 12 atm) balloon inflations were performed until an optimal angiographic result was obtained. In the angiographically guided group, no IVUS imaging was performed. In the IVUS-guided group, IVUS imaging and additional interventions were performed attempting to achieve full apposition, absence of edge tear, and acute gain (lesion lumen area: distal reference lumen area) > or = 0.8 in subsequent IVUS imaging. Total procedure time, fluoroscopy time, contrast media volume, number of balloons, stents, guidewires, guide catheters, and procedural cost were calculated. In hospital abrupt closure rate and 6-month major adverse cardiovascular events (cardiac death, myocardial infarction, target vessel revascularization) rate were obtained.

RESULTS

A total of 178 patients underwent IVUS-guided stent placement and 100 patients underwent angiographically guided stent implantation. There was no significant difference in procedure time (107 +/- 49 vs 100 +/- 50 minutes, P = .22), fluoroscopy time (33 +/- 24 vs 30 +/- 18 minutes, P = .36), contrast volume (411 +/- 157 vs 386 +/- 181 mL, P = .23), guide catheters (1.3 +/- 0.8 vs 1.3 +/- 0.6, P = .69), guidewires (1.6 +/- 1.2 vs 1.6 +/- 1.0, P = .99), balloons (2.4 +/- 1.0 vs 2.3 +/- 1.3, P = .58), and stents (1.7 +/- 0.9 vs 1.6 +/- 0.9, P = .42). Intraprocedural cost was significantly higher in the IVUS-guided group, $4142 +/- 1547 verus $3635 +/- 1949 (P = .03), which was primarily related to the cost of the IVUS catheter. However, the in-hospital acute vessel closure rate was significantly lower in the IVUS-guided group, 0.6% versus 4% (P = .04). There was a trend toward lower target vessel revascularization rate in the IVUS-guided group (11% vs 19%, P = .08). By multivariate analysis IVUS use was demonstrated to be an independent negative predictor of cardiac death, myocardial infarction, repeat revascularization, and abrupt stent closure with a relative risk of 0.49 (95% confidence interval of 0.25 to 0.98), and P = .04.

CONCLUSIONS

The use of IVUS guidance during stent implantation does not significantly increase procedure time, fluoroscopy exposure, contrast volume, or device utilization. Furthermore, despite the increase in procedural cost, IVUS-guided stent implantation is associated with a significant decrease in the in-hospital abrupt closure rate and a trend toward a lower 6-month target vessel revascularization.